EU Healthcare Sector Specialist Commentary

Research evidence excerpt

EU Healthcare Sector Specialist Commentary

Marjan Daeipour - Specialist Sales - European Healthcare AC (44 20) 7134-1329 Europe Specialist Sales J P M O R G A Nmarjan.daeipour@jpmorgan.com

J.P. Morgan Securities plc 30 June 2026

Biotechnology Research:

Jessica Fye (US) Jessica.m.fye@jpmorgan.com+1 212 622 4165

Anupam Rama (US) anupam.rama@jpmorgan.com+1 212 622 0900

Tessa Romero (US) Tessa.T.Romero@jpmorgan.com +1 212 622 4484

Brian Cheng brian.cheng@jpmorgan.com +1 212 622 0449

MedTech Research:

David Adlington (EU) david.adlington@jpmorgan.com+44 207 134 5828

Robbie Marcus (US) robert.j.marcus@jpmorgan.com+1 212 622 6657

Life Science Tool & Diagnostics:

Casey Woodring Casey.Woodring@jpmchase.com+1 212 622 9074

Managed Care, Facilities, Distribution, Technology & PBMs:

Lisa Gill lisa.c.gill@jpmorgan.com+1 212 622 6466

John Stansel John.Stansel@jpmorgan.com+1212 622 0083

Benjamin Rossi Benjamin.Rossi@jpmorgan.com+1 212 622 9603

Alex Comer (CEEMEA) Alex.r.comer@jpmorgan.com+44 207 134 5945

Disclaimers:

This communication is intended for institutional and selected professional clients of J.P. Morgan only. Do not forward outside of your own organization.

You are receiving this email because you are a client of J.P. Morgan. If you would like to stop receiving the Healthcare Sector Specialist Commentary please email Marjan Daeipour at

marjan.daeipour@jpmorgan.com.

This material has been prepared by personnel in the Sales & Trading Department and may include non-independent research (investment recommendations) which, for the purposes of MiFID 2

compliance, may also constitute a marketing communication. As such, this material has not been prepared in accordance with legal requirements designed to promote the independence of Investment